Best Once-Daily Suppressive Antiviral for Genital HSV
Valacyclovir 500 mg once daily is the optimal choice for once-daily suppressive therapy of recurrent genital herpes in immunocompetent adults with normal renal function.
Primary Recommendation
The 1998 CDC guidelines explicitly list valacyclovir 500 mg once daily as a recommended regimen for daily suppressive therapy 1. This is the only antiviral specifically approved for true once-daily dosing for suppression, making it the clear answer to your question about the "best once a day" option.
Key Considerations for Dosing
- Standard frequency patients (fewer than 10 recurrences/year): Valacyclovir 500 mg once daily is highly effective 1, 2
- High-frequency patients (≥10 recurrences/year): The 500 mg once-daily dose appears less effective; these patients should receive valacyclovir 1000 mg once daily OR switch to twice-daily regimens 1
Why Valacyclovir 500 mg Once Daily?
Efficacy: Clinical trials demonstrate that valacyclovir 500 mg once daily prevents or delays 85% of recurrences that would occur with placebo 3. After 16 weeks, 69% of patients remained recurrence-free compared to only 9.5% on placebo 3. The recurrence-free rate remains consistently high across all four quarters of treatment (81-91%) 4.
Convenience and compliance: Once-daily dosing significantly improves adherence compared to multiple daily doses required for acyclovir 5, 6. This is particularly important for long-term suppressive therapy.
Safety profile: Valacyclovir demonstrates comparable safety to placebo, with adverse events being infrequent and generally mild 3. It has been documented as safe for up to 1 year in the guidelines 1, though acyclovir has longer-term safety data (up to 6 years).
Alternative Once-Daily Options
While valacyclovir 500 mg once daily is the primary recommendation, valacyclovir 1000 mg once daily is also listed as an option in the 1998 CDC guidelines 1. This higher dose should be reserved for patients with very frequent recurrences (≥10 episodes/year) where the 500 mg dose proves insufficient.
Important Caveats
Twice-daily regimens remain valid alternatives: If once-daily dosing is not specifically required, acyclovir 400 mg twice daily, famciclovir 250 mg twice daily, or valacyclovir 250 mg twice daily are all acceptable options 1. These may be more effective in high-frequency recurrence patients.
Suppressive therapy limitations: All suppressive regimens reduce but do not eliminate asymptomatic viral shedding, so transmission risk persists even on therapy 1.
Reassessment needed: After 1 year of continuous suppressive therapy, discontinuation should be discussed to reassess the patient's recurrence rate, as frequency often decreases over time 1.
HIV-infected patients require different dosing: The 2009 guidelines specify that HIV-infected persons should receive valacyclovir 500 mg twice daily for suppression, not once daily 7.
Clinical Algorithm
- Confirm indication: Patient has ≥6 recurrences per year
- Assess recurrence frequency:
- <10 recurrences/year → Valacyclovir 500 mg once daily
- ≥10 recurrences/year → Valacyclovir 1000 mg once daily OR twice-daily regimen
- Verify normal renal function (dose adjustment needed if impaired)
- Reassess at 1 year for continued need